Sarah Chen (name changed) built a SaaS company that solved a real problem in healthcare operations. By 2021, her business had reached $8 million in annual recurring revenue with 40% EBITDA margins. She had bootstrapped from zero to a business generating over $3 million in annual profit. When a strategic buyer approached with an offer valued at 8x EBITDA, she declined. Three years later, she sold the same business at 4x EBITDA. The decision cost her approximately $12 million in enterprise value.
This is not a story about a bad founder or poor business execution. Sarah’s company continued to grow revenue after 2021. The business remained profitable. The product roadmap advanced. Yet the outcome illustrates a fundamental truth about company sale timing that many founders learn too late: recognizing the right moment to sell has little to do with predicting the future and everything to do with reading the present accurately.
The 2021 Offer
The strategic buyer in 2021 was a private equity-backed healthcare technology platform executing a roll-up strategy. They had raised $180 million in growth equity six months prior and were aggressively acquiring complementary assets to build a comprehensive suite before an anticipated exit in 24 to 36 months.
The offer structure was straightforward: $24 million in cash at close, representing 8x her trailing twelve-month EBITDA of $3 million. No earnout. No seller note. Clean equity rollover option for 15% of the combined entity if Sarah wanted to participate in the larger platform’s upside. The acquirer had already closed four similar transactions in the previous eighteen months.
Sarah’s reasoning for declining was logical on its surface. Revenue was growing at 35% year-over-year. She had just hired a VP of Sales who was building out the team. Two Fortune 500 healthcare systems were in late-stage pilots that could double her annual contract value if they converted. Her product was gaining recognition in industry publications. She believed the business would be worth significantly more in two to three years.
She was also receiving advice that reinforced this view. Her attorney, who had limited M&A experience, suggested she could “easily get 10x in another year or two.” An advisor who had successfully sold his own company in 2019 told her the healthcare technology market was “just getting started.” Her board, consisting of two angel investors and a successful entrepreneur from a different sector, encouraged her to “keep building.”
What none of these advisors recognized was that the 2021 offer existed within a specific market context that was unlikely to repeat.
The Market Context of 2021
The healthcare technology sector in 2021 operated in an environment of unprecedented capital availability and valuation expansion. Private equity dry powder in the healthcare IT sector exceeded $40 billion. Public market comparables for SaaS businesses were trading at all-time high revenue multiples. SPACs were actively pursuing targets in digital health. Corporate venture arms were writing checks at seed through growth stages with minimal diligence friction.
This capital abundance created multiple effects that elevated valuations for businesses like Sarah’s:
Strategic buyers faced competition from financial buyers, forcing them to pay premium multiples to win deals. Private equity platforms with committed capital needed to deploy proceeds before fund expiration dates, creating urgency that benefited sellers. Public market pressure on growth-stage companies drove acquisitions as a faster path to revenue than organic development. Low interest rates made debt financing for acquisitions inexpensive, allowing buyers to lever up purchase prices without significantly impacting returns.
The 8x EBITDA multiple Sarah received reflected this environment, not necessarily the intrinsic strategic value of her specific business. In a normalized market, a $8 million ARR SaaS business in a specialized vertical with 40% EBITDA margins might command 5x to 6x EBITDA from a strategic buyer, higher from financial buyers focused on consolidation plays.
Sarah’s business was good, but the multiple was exceptional because the market was exceptional.
What Changed Between 2021 and 2024
By mid-2022, the market conditions that created the 8x offer had begun to reverse. The Federal Reserve raised interest rates from near-zero to over 5% in the fastest tightening cycle in four decades. Public market SaaS valuations compressed by 60% to 80% from their 2021 peaks. Venture capital funding for healthcare technology fell from $29.1 billion in 2021 to $15.3 billion in 2023. Private equity deal volume in healthcare IT decreased by 40% year-over-year in 2023.
The strategic buyer who offered 8x in 2021 had completed their roll-up and sold to a larger private equity sponsor in late 2022. The new sponsor immediately shifted focus from growth acquisitions to operational integration and margin improvement. They stopped pursuing add-on acquisitions in early 2023. The window Sarah had declined to enter had closed.
Sarah’s business continued to perform during this period, but the performance occurred in a different valuation environment. Her revenue grew from $8 million in 2021 to $11.5 million by 2024. EBITDA increased from $3 million to $3.8 million. The two Fortune 500 pilots converted into contracts, though at lower annual values than initially projected due to budget constraints at the health systems. She successfully launched a new product module that added a second revenue stream.
By traditional business metrics, Sarah had executed well. Revenue was up 44%. EBITDA was up 27%. The company had expanded its product offering and customer base. Yet when she decided to explore a sale in 2024, the offers she received ranged from 3.5x to 4.2x EBITDA.
The final transaction closed at 4x EBITDA, or $15.2 million in enterprise value. After transaction costs and employee retention bonuses, Sarah netted approximately $13.5 million. Had she accepted the 2021 offer, she would have netted approximately $22 million after comparable costs (the tax treatment would have been similar in both scenarios, as both were structured as stock sales qualifying for long-term capital gains treatment).
The Timing Fallacy
Founders often approach company sale timing as a prediction problem. They attempt to forecast when their business will be worth more, when market conditions will improve, or when strategic buyers will emerge with premium offers. This framing is fundamentally flawed.
Sell my company timing is not about predicting the future. It is about recognizing the present with clarity and acting on what is observable rather than what is hoped for.
In 2021, several present-tense indicators suggested Sarah was receiving an exceptional offer:
The multiple was 30% to 60% higher than historical norms for comparable businesses. The buyer was offering all cash at close with no earnout or retention requirements beyond a standard 90-day transition. Strategic buyers in her space were actively competing for assets, creating a seller’s market. Financing for acquisitions was readily available and inexpensive. The broader M&A environment showed strong volume and rising valuations across sectors.
These were not predictions about the future. They were observable facts about the present that suggested the current offer might represent a local maximum for valuation.
Conversely, several factors suggested that sustaining or expanding this valuation would require near-perfect execution and continued favorable market conditions:
The business was growing but not at a rate that would justify multiple expansion (35% growth is strong but not the 60% to 100% growth rates that command premium valuations in SaaS). The market was competitive with no significant barriers to entry beyond brand and customer relationships. Her product was good but not a category-defining innovation that would attract acquirer premiums. The company was still relatively small in absolute terms, limiting the pool of potential strategic buyers.
Sarah’s decision to decline was based on a prediction that these present conditions would continue or improve. She predicted the market would remain favorable. She predicted her growth rate would accelerate. She predicted strategic buyers would continue to pay premium multiples. She predicted that her execution over the next two to three years would create more value than accepting the current offer.
Some of these predictions proved correct. Her execution was strong. Her growth continued. But the market prediction proved incorrect, and that single variable overwhelmed the others.
The Recognition Framework
If timing is about recognition rather than prediction, what should founders recognize?
The first element is market positioning. This refers to where valuations currently stand relative to historical norms. In any given sector, multiples paid for acquisitions fluctuate within a range over time. When current multiples are at or near the top of that historical range, it indicates premium pricing in the present market. This is observable through public comparable analysis, recent transaction multiples in your sector, and discussions with M&A advisors who track deal flow.
Sarah’s 8x EBITDA offer in 2021 was at the high end of what similar businesses had commanded in the previous decade. This was recognizable at the time, not in hindsight.
The second element is buyer motivation intensity. Different buyers pursue acquisitions with different levels of urgency at different times. A strategic buyer executing a roll-up strategy with committed capital and a defined timeline has higher urgency than an opportunistic buyer casually exploring inorganic growth. A buyer who has already closed multiple similar transactions and knows how to value and integrate your type of business moves faster and pays more predictably than a first-time acquirer.
The 2021 buyer had closed four similar deals, had fresh capital, and was operating on a 24 to 36-month exit timeline. This created urgency that worked in Sarah’s favor. By 2024, most active consolidators in her space had either completed their roll-ups or shifted strategies.
The third element is business trajectory requirements. Every business needs certain things to happen to justify a higher future valuation: accelerating growth, expanding margins, launching successful new products, entering new markets, or building competitive moats. Founders should assess how many of these things need to go right, how much control they have over the outcomes, and what happens to valuation if only some of them succeed.
Sarah needed her two large pilots to convert at projected values, her sales team build-out to drive acceleration in new customer acquisition, her new product module to achieve significant adoption, and favorable market conditions to continue. She had direct control over product development and team hiring, partial influence over customer decisions, and no control over market conditions. The more variables required for success, the higher the risk of valuation disappointment.
The fourth element is founder personal readiness. This is often overlooked in timing discussions, but it is critical. Founders who are energized, engaged, and genuinely excited about the next three to five years of building will create more value than founders who are tired, distracted, or ambivalent. If accepting an offer means walking away from work you genuinely want to do, that is a real cost that should factor into the decision. If declining an offer means committing to three more years of intense work you are not sure you want to do, that is a risk to business performance.
Sarah was energized in 2021, which was a legitimate reason to keep building. By 2024, she was experiencing founder fatigue common in year seven to eight of company building. This affected her willingness to grind through the operational challenges of scaling past $15 million in ARR.
The Opportunity Cost of Waiting
The $12 million difference between the 2021 and 2024 outcomes represents direct opportunity cost, but the full cost of Sarah’s timing decision extends beyond the nominal dollar difference.
From a time-value-of-money perspective, $22 million received in 2021 could have been deployed into diversified investments immediately. Assuming a conservative 7% annual return over three years, that capital would have grown to approximately $27 million by 2024. The actual outcome of $13.5 million in 2024 represents a total opportunity cost of roughly $13.5 million when accounting for both the lower sale price and the lost investment returns.
There is also the personal opportunity cost of three additional years of operating intensity. Sarah remained the primary decision-maker and problem-solver for her business throughout this period. She managed team scaling challenges, customer success issues, product development decisions, and competitive responses. These responsibilities carried stress, consumed time, and limited her ability to pursue other interests or opportunities.
The counterfactual where she accepts the 2021 offer includes three years of freedom to pursue new projects, spend time with family, engage in advisory or investing activities, or simply rest and recharge. The value of that time is personal and subjective, but it is real.
When the Prediction Approach Works
There are circumstances where founders who decline current offers and wait for future opportunities create substantial value. These situations typically share certain characteristics.
The business is in a genuinely early stage of an adoption curve where massive growth is not hoped for but is mechanically probable based on market dynamics. The founder has line of sight to specific, controllable actions that will dramatically change the business profile (such as a pending enterprise contract that will triple ARR, a product launch that opens an entirely new market, or a regulatory approval that creates a competitive moat). The current offer is coming from a weak position (distressed sale, limited buyer interest, below-market multiple) rather than from a position of strength.
Sarah’s situation in 2021 did not fit these criteria. Her market was mature. Her growth was solid but not explosive. Her business had already achieved good scale and profitability. The offer was strong, not weak. Her decision to wait was based on optimism about continued favorable conditions, not on specific, controllable value creation opportunities.
The Role of Professional M&A Advisors
One consistent pattern in poorly timed exit decisions is the absence of experienced M&A advisory services during the critical evaluation period. Sarah received input from her attorney, her existing advisors, and her board, but none of these parties had deep expertise in her sector’s M&A market or recent transaction experience.
Professional sell-side mergers and acquisitions advisors bring specific capabilities that prove valuable in timing decisions:
They maintain current knowledge of transaction multiples, deal structures, and buyer appetite in specific sectors. They can contextualize an offer against recent comparable transactions to determine whether it represents premium, market, or below-market pricing. They understand buyer motivations and can assess whether current buyer interest represents typical activity or elevated demand. They can model different scenarios to illustrate the execution requirements and market assumptions embedded in a “wait and build more value” decision.
In Sarah’s case, an experienced advisor in 2021 would have been able to provide data showing that 8x EBITDA for a business of her profile was in the 90th percentile of recent transactions, that the healthcare IT M&A market was experiencing unusually high activity and valuations, and that the all-cash, no-earnout structure was advantageous compared to the earnout-heavy deals that often characterize smaller transactions.
This type of exit readiness analysis does not make the decision for the founder, but it provides the factual foundation for recognizing the current opportunity clearly.
Lessons for Founder Timing Decisions
Sarah’s experience offers several practical lessons for founders evaluating company sale timing:
Focus on Present Recognition Over Future Prediction: Assess the quality of your current offer against observable market data, not against your hopes for future offers. If the present offer is strong relative to historical norms and your business fundamentals, the burden of proof should rest on the decision to wait, not on the decision to sell.
Discount Your Own Optimism: Founders are dispositionally optimistic about their businesses. This optimism is necessary for building companies but becomes a liability in M&A decisions. When evaluating whether to wait for a higher valuation, explicitly identify what needs to go right, assess your control over those variables, and consider what happens if only 50% of your optimistic projections materialize.
Understand That Markets Are Not Linear: Business performance and market valuations do not move in lockstep. A business can improve while its market valuation decreases if the broader environment changes. Macro factors (interest rates, public market comparables, private equity deployment pace, sector-specific investor sentiment) often matter more than micro improvements in your specific business.
Separate Business Building from Exit Timing: The question “should I sell now?” is different from the question “do I want to keep running this business?” Founders who genuinely want to keep building should keep building, but they should do so with clear eyes about the valuation implications of that choice. Founders who are ready to exit should not talk themselves into waiting simply because they think the business might be worth more later.
Get External Calibration: Before making a significant timing decision, engage advisors who have recent, relevant transaction experience in your sector. Their perspective will not perfectly predict the future, but it will help you recognize the present more accurately.
The Outcome in Perspective
Sarah netted $13.5 million from her 2024 sale. By any objective standard, this represents a successful outcome. She built a business from nothing, created jobs, solved real problems for customers, and achieved financial security. The focus on the $12 million in opportunity cost should not diminish that accomplishment.
However, when founders make decisions about company sale timing, they are making decisions with millions of dollars at stake. Small differences in judgment, timing, or market recognition can result in large differences in outcomes. The discipline required is to see the situation clearly, not as you hope it will be.
Sarah’s reflection three months after closing captures this: “I spent three years trying to predict when the market would reward my business more. I should have spent three weeks recognizing how much the current market was already rewarding it. Timing isn’t predicting. It’s recognizing.”
For founders currently evaluating offers or considering when to take their business to market, this distinction matters. The market you are in today is real. The offers you receive today reflect actual buyer appetite and actual capital availability. The market you hope to be in two years from now is a forecast, subject to all the uncertainties that forecasts entail.
The skill is not in predicting which way the wind will blow tomorrow. The skill is in recognizing when the wind is at your back today and making the decision to move while it is.
